Real-time reactions to earnings, macro events and market moves — what actually happened, what the numbers show, and what we’re doing about it in our own positions. Not price predictions, a working read on the stocks and events moving the market this week.
Danaher’s EPS fell from $9.66 to $5.05 in three years, yet its P/E is 37.6 against a 36.3 average. After an 11% drop on the July report, a look at the margin, the multiple, and…
Pfizer pays $0.43 every quarter, but net income over the last four reported quarters was $4.37 billion against a $9.8 billion dividend bill. Why the 6.2% yield is a bet on 2027 cost cuts, with…
Lam Research had a record $6.72 billion quarter and an 18% one-day pop, yet it sits 34% below its 52-week high. At 50 times earnings, earnings would have to nearly double to justify the price…
Coca-Cola’s operating margin has risen three years in a row to 31.1%. The P/E of 26.5 looks average, but price to sales sits at the 99th percentile of its range. A look at what a…
Salesforce jumped 22.6% after its August report while our quant score sits at a D. At $238 and 21.8 times earnings, here is what the reported numbers say about Agentforce, margins, valuation, and the one…
Regeneron’s June quarter had $2.455 billion of partner revenue against about $1.35 billion from its own drugs. At $785 and 19.4 times earnings, here is what the mix means for growth, the forward P/E, and…
Energy Transfer yields 6.32%, but a K-1 costs the same for a $5,000 holder as for a $50,000 one. The bigger issue is cash cover: free cash flow paid only 0.81x of the distribution in…
Chevron’s latest quarter brought $67.2 billion of revenue, up 51%, after three years of shrinking profit. At about $210 and 14 times forward earnings, here is what the market already assumes, a price grid, and…
AMD’s revenue finally caught up with its roadmap: sales rose 50% last quarter. The stock rose faster, up 3.6 times from its low, and at 144 times trailing earnings it is priced for years of…
AbbVie earns $3.54 a share on trailing numbers and about $10.25 on forward ones. Skyrizi and Rinvoq now make up 47% of sales after the Humira cliff. Here is which EPS to believe, a price…